HB3631 creates a new criminal offense under 18 U.S.C. §1041 for medical research companies or sponsors that make fraudulent statements to, or conceal material data from, U.S. government vaccine trials. The offense carries fines and up to five years in prison.
The bill also revises the vaccine-authorization framework by requiring a certification from a sponsor that no fraudulent statements were made and no material information was concealed, as a condition of eligibility for approval. In addition, it expands liability and remedies across several existing laws, including adjustments to the Right to Try statute, the Pandemic and Epidemic Products liability protections, and the National Vaccine Injury Compensation Program, and it establishes a formal liability-hearing process.
The overall aim is to deter fraud in vaccine testing, strengthen accountability across regulators and sponsors, and expand avenues for compensation where fraud is proven.
At a Glance
What It Does
The bill adds a criminal fraud offense for clinical vaccine trial data, requires a fraud-free certification for regulatory authorization, and broadens liability and compensation rules related to vaccines.
Who It Affects
Medical research companies and sponsors, FDA and other federal agencies, vaccine manufacturers, clinical trial sites, and researchers.
Why It Matters
By elevating data integrity to criminal status and tightening authorization and compensation regimes, the bill seeks to deter fraud, protect patients, and clarify consequences for misrepresentation in vaccine trials.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The VITAL Act of 2025 targets fraud in clinical vaccine trials by creating a new criminal offense for sponsors or medical research companies that knowingly submit fraudulent data or conceal material information. This offense sits in the federal criminal code (18 U.S.C. §1041) and carries penalties including fines and up to five years’ imprisonment.
The bill also changes how a vaccine is authorized for use by requiring a sponsor to certify that no fraudulent material statements were made and that no material data was concealed in relation to the trial data used to support the approval decision. The changes extend beyond criminal penalties to modify liability protections and remedies for vaccines, including amendments to the Right to Try Act and the Public Health Service Act, and by adding a formal process for liability hearings.
Finally, the act codifies new standards within the National Vaccine Injury Compensation Program, ensuring that fraud-related claims can be pursued alongside other avenues for damages.
The Five Things You Need to Know
New criminal offense (18 U.S.C. §1041) for fraudulent statements or concealment in clinical vaccine trials with penalties up to 5 years’ imprisonment.
FDA authorization now requires a sponsor certification that no fraudulent data was used or concealed in relation to trial data.
Liability frameworks for vaccines are expanded, including Right to Try and pandemic product protections.
The National Vaccine Injury Compensation Program is amended to cover fraud-related damages and allow concurrent civil litigation.
A formal liability hearing process is established, with publication of evidence and a 30-day refutation window.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Clinical vaccine trial fraud offense
This section adds a new criminal offense to 18 U.S.C. for sponsors or medical research companies that make fraudulent statements to, or conceal material data from, any department or agency evaluating a clinical vaccine trial. The offense carries fines, imprisonment for up to five years, or both. The provision gives federal prosecutors a clear basis to pursue fraud in trial data, strengthening the deterrent against data manipulation or misrepresentation in vaccine development.
Scope of authorization (certification requirement)
This section amends the FDA authorization framework by requiring that an authorization be based, in part, on a certification from the sponsor that there were no fraudulent material statements and no concealed material data relating to the trial. It ties certification to the validity of the underlying data and to the integrity of the data package that supports regulatory decisions.
Revision and revocation powers
This section revises existing authorization provisions to allow revocation or denial of approvals if fraud or concealed information is found in the trial data or related circumstances. It strengthens the government’s ability to intervene when material misrepresentations have occurred, potentially leading to withdrawal of already granted approvals.
Right to Try liability exceptions expanded
Amends the Right to Try framework to account for fraudulent data or concealed information in clinical trials of investigational drugs. It ensures that fraud-related data issues can influence outcomes under this program, and it clarifies how such issues should be treated in the context of liability and eligibility for experimental therapies.
Pandemic/epidemic product liability protections
Amends sections related to pandemic and epidemic countermeasures to include fraud or concealed information in clinical trial data as grounds for liability determination or denial of protections, introducing a more nuanced set of conditions under which pandemic products may be evaluated and held accountable.
National Vaccine Injury Compensation Program changes
Adds liability provisions to the PVICP, allowing fraud-related statements or concealed data to trigger claims for damages and permitting concurrent civil actions in appropriate courts. It also defines a broader set of circumstances under which damages may be awarded and clarifies the interaction between PVICP awards and other potential remedies, including COVID-19 vaccine considerations.
Liability hearing process
Establishes a formal hearing process for fraud-related liability determinations, including timelines for document production, format of hearings, and publication of testimony or evidence on a government website. The process is designed to provide due process while ensuring transparency in fraud allegations and determinations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal regulators (HHS/FDA/DOJ) gain clearer enforcement authority and a defined fraud standard for vaccine trial data, enabling swifter action against misconduct.
- Clinical trial participants and the public benefit from more trustworthy data and safer vaccines.
- Vaccine sponsors and medical research organizations that comply with data integrity standards may operate in a clearer, accountability-driven environment.
- FDA reviewers and inspectors gain a standardized framework to assess data integrity and enforce compliance.
- Whistleblowers and investigators in trial data gain clearer pathways to report and support fraud investigations.
Who Bears the Cost
- Medical research companies and sponsors face criminal penalties, potential fines, and heightened compliance expectations.
- Trial sites and contract research organizations must implement stricter data handling and reporting protocols, increasing administrative burdens.
- Courts and prosecutors may see a higher volume of fraud-related cases, with associated resource needs.
- Regulators may incur costs to administer new hearings and publish proceedings.
- Healthcare providers could experience indirect costs from a more complex liability landscape and compliance requirements.
Key Issues
The Core Tension
Deterring fraud in vaccine trials while preserving the pace and feasibility of legitimate vaccine development and data sharing; expanding liability and enforcement may improve integrity but could also raise barriers for smaller sponsors or slow rolling out beneficial vaccines.
The bill creates strong incentives to ensure the integrity of data in vaccine research, but it also raises questions about the risks of deterring legitimate data sharing or slowing innovation if compliance costs become prohibitive for smaller sponsors. The combination of criminal penalties, certification requirements, and expanded liability could raise the bar for trial reporting and increase enforcement actions, which is appropriate for fraud deterrence but may affect the pace of certain vaccine developments.
The interactions between criminal fraud provisions, civil liability reforms, and PVICP adjustments require careful consideration to avoid duplicative or conflicting remedies or unintended exclusions of legitimate claims. The liability-hearing process adds transparency but also introduces potential delays in enforcement decisions that affect public health responses, particularly in urgent vaccine scenarios.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.